Aspirin Linked to 70% Reduced Dementia Risk in Seniors
Aspirin use in a specific senior group shows a significant reduction in dementia risk, but also increased bleeding risk.
A recent study published in "Alzheimer’s & Dementia" indicates that aspirin may be associated with a 70% reduction in dementia risk among a specific group of seniors. However, this benefit comes with a more than twofold increase in the risk of serious bleeding. The study analyzed data from 13,541 participants in the ASPREE trial, where individuals took either 100 mg of aspirin or a placebo daily. Researchers investigated whether genetic factors influenced the response to the medication.
Study Findings
The analysis revealed that while aspirin was beneficial for a subset of participants, approximately 80% of the group did not experience any protective effects against dementia. Neurologist Dr. Alexander Zubkov emphasized that the findings do not suggest that individuals with elevated platelet counts in routine blood tests should take aspirin. The genetic indicator analyzed reflects hereditary predisposition based on various DNA variants.
Dr. Luke Sorrell, an internist, noted that individuals in this group might have normal platelet counts in laboratory tests. Platelets play a role in clot formation, and aspirin inhibits their activation, which could potentially limit damage to small brain vessels. However, the mechanism remains hypothetical, as the genetic indicator does not directly measure platelet activity.
In the subgroup that may benefit from aspirin, serious bleeding occurred in 4.4% of those taking the drug compared to 2.1% in the placebo group, resulting in a 2.3 percentage point absolute increase. Despite these numerical differences, they do not imply identical health consequences for both events.
Dr. Sorrell highlighted the importance of noting that bleeding occurred approximately twice as often in the group that appeared to benefit from aspirin. This exploratory analysis is not a trial specifically designed for this genetic group, and the results require confirmation before influencing clinical recommendations. The authors stress that at this stage, the findings primarily guide future research directions and should not be the basis for starting aspirin for memory protection. Patients prescribed aspirin for other indications should not discontinue the medication without consulting their healthcare provider.
